Avalyn Pharma Inc. operates as a clinical-stage biopharmaceutical company developing inhaled medicines to treat rare respiratory diseases, including pulmonary fibrosis and other interstitial lung diseases. The company provides inhaled formulations of oral medicines directly to the lungs. Its current pipeline is focused on treating pulmonary fibrosis. Its products include AP01 and AP02, inhaled formulations of pirfenidone and nintedanib for the treatment of progressive pulmonary fibrosis and idiopathic pulmonary fibrosis; and AP03, a fixed-dose combination of inhaled pirfenidone and nintedanib to deliver dual antifibrotic mechanisms. Avalyn Pharma Inc. was formerly known as Genoa Pharmaceuticals, Inc. and changed its name to Avalyn Pharma Inc. in July 2017. The company was incorporated in 2011 and is based in Boston, Massachusetts. Show more

105 W First Street, Boston, MA, 02127, United States

Biotechnology

Healthcare

Market Cap

1.275B

52 Wk Range

$24.15 - $32.23

Previous Close

$28.75

Open

$28.26

Volume

190,876

Day Range

$28.01 - $29.78

Enterprise Value

1.168B

Cash

123.1M

Avg Qtr Burn

-29.89M

Insider Ownership

0.00%

Institutional Own.

49.91%

Qtr Updated

03/31/26

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & Indication	Stage & Event	Catalyst Date
Nintedanib (AP02) (Antifibrotic Therapy) Details Idiopathic Pulmonary Fibrosis	Phase 2 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Nintedanib/Pirfenidone (AP03) (Antifibrotic Combination) Details Pulmonary Fibrosis	Phase 1 Initiation	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.